Aurinia Pharmaceuticals Inc. (TSE:AUP – Get Free Report) (NASDAQ:AUPH) shares traded down 3.5% during mid-day trading on Monday . The company traded as low as C$16.41 and last traded at C$16.76. 4,611,683 shares were traded during trading, an increase of 1,906% from the average session volume of 229,895 shares. The stock had previously closed at C$17.37.
Aurinia Pharmaceuticals Price Performance
The company has a market capitalization of C$2.15 billion and a PE ratio of -11.32. The company’s 50 day simple moving average is C$16.76. The company has a quick ratio of 11.02, a current ratio of 11.93 and a debt-to-equity ratio of 2.69.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
See Also
- Five stocks we like better than Aurinia Pharmaceuticals
- What is the S&P/TSX Index?
- Tesla Poised to Hit Record Highs This Holiday Season
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- The Salesforce Rally is Just Getting Started: Here’s Why
- How Technical Indicators Can Help You Find Oversold Stocks
- 3 Chip and Data Center Stocks That Can Keep Rising in 2025
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
